Edition:
United States

Karolinska Development AB (KDEV.ST)

KDEV.ST on Stockholm Stock Exchange

5.05SEK
26 May 2017
Change (% chg)

-0.05kr (-0.98%)
Prev Close
5.10kr
Open
5.05kr
Day's High
5.10kr
Day's Low
4.78kr
Volume
66,819
Avg. Vol
22,009
52-wk High
9.05kr
52-wk Low
4.78kr

Latest Key Developments (Source: Significant Developments)

Karolinska Development's Dilafor raises SEK 51 million for study
Tuesday, 27 Sep 2016 02:00am EDT 

Karolinska Development Ab : Karolinska Development portfolio company Dilafor AB raises 51 million Swedish crowns ($6 million) to facilitate phase IIb clinical study with tafoxiparin . Financing has no impact on Karolinska Development's fair value . As a result of new financing, Karolinska Development has decreased its indirect holdings via KDev investments in Dilafor from 53% to 35% .Successful completion of financing round enables Dilafor to facilitate a phase IIb dose finding trial with tafoxiparin trial in northern europe.  Full Article

Karolinska Development Q2 net sales fall to SEK 0.6 mln
Wednesday, 31 Aug 2016 02:42am EDT 

Karolinska Development AB : Net sales amounted to 0.6 million Swedish crowns ($70,000) in Q2 (1.1 million crowns in Q2 2015) .Operational costs in Q2 amounted to 6.6 million crowns, a reduction of 46 pct compared to 12.2 million crowns in Q2 2015.  Full Article

Karolinska Development divests holding in Clanotech to Rosetta Capital
Tuesday, 5 Jul 2016 02:08am EDT 

Karolinska Development AB : Says KDev Investments, investment fund jointly owned by Karolinska Development and Rosetta Capital, will transfer all its shares in Clanotech to Rosetta Capital . Portfolio Net Fair Value will decrease by 54.8 million Swedish crowns ($6.49 million) .Retains an economic interest in company through an earn-out agreement.  Full Article

Karolinska Development: Lipidor and Cadila Pharmaceuticals agree on Phase III study and sale of Psoriasis product
Wednesday, 1 Jun 2016 02:00am EDT 

Karolinska Development AB : Lipidor and Cadila Pharmaceuticals announce agreement on Phase III clinical study and joint commercialization of topical Psoriasis product . Lipidor and Cadila Pharmaceuticals have entered into collaboration agreement on commercialization of sprayable anti-psoriatic product consisting of generic Vitamin D analogue, Calcipotriol, formulated with Lipidor´s patented lipid-based drug delivery technology, AKVANO . Product targets patients with mild to moderate psoriasis .Under collaboration agreement, Cadila Pharmaceuticals will conduct a Phase III program in India starting in 2016.  Full Article

Karolinska Development Q1 net sales fall to SEK 0.6 million
Tuesday, 10 May 2016 02:12am EDT 

Karolinska Development AB : Q1 net sales 0.6 million Swedish crowns ($75,000) versus 1 million crowns year ago .Q1 operating loss for Investment Entity 90.1 million crowns versus loss 241.8 million crowns year ago.  Full Article

Karolinska Development says portfolio company Aprea raises SEK 437 mln
Wednesday, 9 Mar 2016 02:00am EST 

Karolinska Development AB:Says its portfolio company Aprea raises 437 million Swedish crowns in a Series B financing round.‍Aprea is investigating APR-246 in phase Ib/II clinical study in high-grade serous ovarian cancer​‍.New funds will be used by Aprea to advance clinical development of its lead cancer program​.Company is planning to conduct exploratory trials in other cancer indications​.  Full Article

Karolinska Development AB: Akinion halts development of AKN-028 due to safety concerns
Friday, 4 Mar 2016 02:00am EST 

Karolinska Development AB:Portfolio company Akinion halts further development of AKN-028 due to safety concerns.‍Portfolio net fair value will decrease by 78 million Swedish crowns.‍Halt in development due to a small number of patients experiencing severe liver toxicity​.  Full Article

Karolinska Development AB: Dilaforette signs agreement with Arabian Gulf University
Tuesday, 16 Feb 2016 02:00am EST 

Karolinska Development AB:Portfolio company Dilaforette AB and Arabian Gulf University (AGU) in Bahrain, have signed a Clinical Collaboration agreement for the Phase 2 proof of concept trial of sevuparin in patients with Sickle Cell Disease (SCD) experiencing acute Vaso-Occlusive Crisis (VOC).Results from this phase 2 proof of concept trial with sevuparin are expected in H2 2016​ ‍.AGU will provide up to $1.2 million in non-dilutive funding for study and assist with patient recruitment.In return AGU will receive royalties on future product revenues which are capped at twice the financial support it provides to the Phase 2 proof of concept study​.Dilaforette AB is a company focused on treatments for patients with sickle-cell disease.  Full Article

Karolinska Development and Karolinska Institutet sign non-exclusive deal flow agreement
Tuesday, 22 Dec 2015 02:00am EST 

Karolinska Development AB:Says the company and Karolinska Institutet Holding AB sign new non-exclusive deal flow agreement.Aim of the deal is to improve the translation of medical innovations into successful commercial enterprises.As part of the new agreement, Karolinska Institutet plans to establish a new incubator fund initiative focused on identifying potentially valuable new medical innovations.Karolinska Development will be a cornerstone investor in the new incubator fund.Will be able to source opportunities from other academic institutions across the Nordic region.  Full Article

Karolinska Development AB divests its holding in Athera Biotechnologies
Thursday, 3 Dec 2015 02:00am EST 

Karolinska Development AB:Divests its holding in Athera Biotechnologies.Divests to a consortium led by Foundation for Baltic and East European Studies.Concurrently consortium invests 24 million Swedish crowns into Athera to fund further clinical development of Athera's lead project PC-mAb.Divestment has no impact on latest reported fair value.No further financial details on this transaction will be disclosed.  Full Article

More From Around the Web